<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="369422">
  <stage>Registered</stage>
  <submitdate>2/10/2015</submitdate>
  <approvaldate>8/12/2015</approvaldate>
  <actrnumber>ACTRN12615001340527</actrnumber>
  <trial_identification>
    <studytitle>A First in Human Assessment of Safety and Performance of the Apama Radiofrequency (RF) Balloon Catheter System to Isolate Pulmonary Veins in  the  Treatment of Paroxysmal Atrial Fibrillation</studytitle>
    <scientifictitle>A First In Human Radiofrequency (RF) Balloon Catheter Ablation to Isolate Pulmonary Veins in the Treatment of Patients with Paroxysmal Atrial Fibrillation</scientifictitle>
    <utrn>U1111-1175-1054 </utrn>
    <trialacronym>AF-FICIENT  AF </trialacronym>
    <secondaryid>Nil</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>atrial fibrillation</healthcondition>
    <healthcondition>paroxysmal atrial fibrillation</healthcondition>
    <healthcondition>persistent atrial fibrillation</healthcondition>
    <conditioncode>
      <conditioncode1>Cardiovascular </conditioncode1>
      <conditioncode2>Other cardiovascular diseases</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Surgery</conditioncode1>
      <conditioncode2>Surgical techniques</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Apama RF Balloon Catheter system used for radiofrequency ablation; RF energy administered to tissue at 8-10 Watts power over durations of 60 - 90 seconds with irrigation of 30 ml/minute. Procedural times can vary from one hour to approximately three hours depending upon the ability to isolate veins using radiofrequency and to restore rhythm to normal sinus. </interventions>
    <comparator>No Control Group </comparator>
    <control>Uncontrolled</control>
    <interventioncode>Treatment: Devices</interventioncode>
    <interventioncode>Diagnosis / Prognosis</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Acute Safety assessed by the ability to deliver radiofrequency ablation with absence of device or procedure related serious adverse events following the procedure. Risks associated with this procedure are equal to those of other electrophysiological cardiac procedures including heart rhythm disturbances, blood clots, ischemic event. Transthoracic Echocardiography will be performed at discharge or 7 days post procedure whichever occurs first. </outcome>
      <timepoint>Echocardiography performed at 7 days post procedure </timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Performance based on the clinical success of pulmonary vein isolation as defined by 12 lead ECG and Transthoracic Echo to confirm pulmonary vein isolation and confirmation of exit or block.</outcome>
      <timepoint>30 days post procedure</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>History of symptomatic paroxysmal and or persistent atrial fibrillation within the past year documented by ECG
Suitable candidate for catheter non-emergent intra-cardiac mapping and ablation </inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>75</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Structural heart disease of clinical significance including previous cardiac surgery (excluding CABG or mitral valve repair)
Documented EF &lt;30%
Left atrial diameter of &gt;55mm
Contraindication to anticoagulation therapy
Unstable angina or ongoing myocardial ischemia
Myocardial infarction within 3 months of enrollment
Congenital heart disease where the underlying abnormality increases the risk 	of the ablation                                                        
Prior Atrial Septal Defect or Patent Foramen Ovale Closure with a device using a transcatheter percutaneous approach 
Hypertrophic cardiomyopathy (LV septal wall thickness &gt;1.5cm)
Pulmonary hypertension (&gt;50mm Hg)
Prior ablation for atrial fibrillation
Enrollment in any other ongoing arrhythmia study protocol
Patients with severely impaired kidney function as measured by Cockcroft-Gault Glomerular Filtration Rate (GFR) 3 with a GFR &lt; 29
Active gastrointestinal bleeding, infection or fever (&gt;100.5/38C) or sepsis
Short life expectancy (&lt;1 year) due to illness such as cancer, pulmonary,hepatic or renal disease
Significant anemia (hemoglobin &lt; 8.0 / dl)
Severe uncontrolled systemic hypertension with systolic &gt;200mm Hg within ast 30 days
Documented anaphylaxis during previous exposure to contrast media
Bleeding or clotting disorders or thrombotic disorder under treatment
Uncontrolled diabetes
Women who are pregnant and not willing to use contraception for the duration of the study
Severe COPD (identified by an FEV1 &lt;1)
Unwilling or unable to comply with any protocol or follow up requirements
</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Non-randomised trial</allocation>
    <concealment />
    <sequence />
    <masking>Open (masking not used)</masking>
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint>Safety</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry>False</patientregistry>
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate>5/01/2016</anticipatedstartdate>
    <actualstartdate>8/03/2016</actualstartdate>
    <anticipatedenddate>20/10/2017</anticipatedenddate>
    <actualenddate />
    <samplesize>30</samplesize>
    <actualsamplesize />
    <currentsamplesize>40</currentsamplesize>
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>,Outside</recruitmentcountry>
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Christchurch</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Wellington </state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Paraguay</country>
      <state>Asuncion</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Czech Republic</country>
      <state>Prague</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Other</primarysponsortype>
    <primarysponsorname>Apama Medical </primarysponsorname>
    <primarysponsoraddress>745 Camden Suite# A
Campbell, CALIFORNIA 95008 </primarysponsoraddress>
    <primarysponsorcountry>United States of America</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Commercial sector/Industry</fundingtype>
      <fundingname>Apama Medical </fundingname>
      <fundingaddress>745 Camden Avenue Suite A
Campbell, CALIFORNIA 95008</fundingaddress>
      <fundingcountry>United States of America</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname>None </sponsorname>
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>The study is intended to assess the safety and preliminary performance data for treatment of symptomatic paroxysmal atrial fibrillation using the Apama Cardiac Ablation System. The study will be a prospective, multicenter, non-randomized investigation.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Health and Disability Ethics Committees </ethicname>
      <ethicaddress>Ministry of Health
C/-MEDSAFE, Level 6, Deloitte House
10 Brandon Street
PO Box 5013 Wellington 6011</ethicaddress>
      <ethicapprovaldate>11/11/2015</ethicapprovaldate>
      <hrec />
      <ethicsubmitdate>20/10/2015</ethicsubmitdate>
      <ethiccountry>New Zealand</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>Prof</title>
      <name>Ian Crozier </name>
      <address>Christchurch Hospital
2 Riccarton Avenue
PO Bag 4710
Christchurch 8140</address>
      <phone>+643640640</phone>
      <fax>+6433786378</fax>
      <email>Ian.Crozier@cdhb.health.nz</email>
      <country>New Zealand</country>
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title>Ms</title>
      <name>Joann Heberer</name>
      <address>Apama Medical
745 Camden Avenue Suite A
Campbell, California 95008</address>
      <phone>+6508689417</phone>
      <fax>+9494940557</fax>
      <email>jheberer@apamamedical.com</email>
      <country>United States of America</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title>Ms</title>
      <name>Laura Minarsch</name>
      <address>MMC Medical 
430 Forest Avenue
Laguna Beach, California 92651</address>
      <phone>+9492805700</phone>
      <fax>+9494940557</fax>
      <email>laura22@mmc-medical.com</email>
      <country>United States of America</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title>Ms</title>
      <name>Laura Minarsch </name>
      <address>430 Forest Ave 
Laguna Beach, California 92651 </address>
      <phone>+9494945048</phone>
      <fax>+9494940557</fax>
      <email>laura22@mmc-medical.com</email>
      <country>United States of America</country>
      <type>Updating Information</type>
    </contact>
  </contacts>
</ANZCTR_Trial>